Pacira BioSciences, Inc. Forecasted to Post FY2022 Earnings of $3.39 Per Share (NASDAQ:PCRX)

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Investment analysts at Jefferies Financial Group upped their FY2022 earnings per share estimates for shares of Pacira BioSciences in a research report issued on Tuesday, January 11th. Jefferies Financial Group analyst D. Steinberg now forecasts that the company will post earnings of $3.39 per share for the year, up from their prior estimate of $3.29.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Tuesday, November 2nd. The company reported $0.72 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.07. Pacira BioSciences had a net margin of 12.01% and a return on equity of 14.39%. The company had revenue of $127.70 million for the quarter, compared to analyst estimates of $129.69 million. During the same period in the prior year, the business earned $0.43 earnings per share. Pacira BioSciences’s quarterly revenue was up 8.7% on a year-over-year basis.

Several other equities analysts have also weighed in on the stock. JPMorgan Chase & Co. initiated coverage on shares of Pacira BioSciences in a report on Monday, January 3rd. They issued an “overweight” rating and a $83.00 price objective on the stock. BMO Capital Markets cut their price objective on shares of Pacira BioSciences from $66.00 to $60.00 and set a “market perform” rating on the stock in a report on Tuesday, October 12th. Wedbush restated a “buy” rating and issued a $97.00 price objective on shares of Pacira BioSciences in a report on Friday, January 7th. Needham & Company LLC increased their price objective on shares of Pacira BioSciences from $80.00 to $84.00 and gave the company a “buy” rating in a report on Monday, October 18th. Finally, HC Wainwright increased their price objective on shares of Pacira BioSciences from $80.00 to $86.00 and gave the company a “buy” rating in a report on Thursday, November 4th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $81.09.

Shares of PCRX stock opened at $64.08 on Thursday. The firm’s 50 day moving average is $57.85 and its 200-day moving average is $56.90. Pacira BioSciences has a 1 year low of $45.05 and a 1 year high of $80.00. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of 47.12 and a beta of 1.00. The company has a current ratio of 3.64, a quick ratio of 3.34 and a debt-to-equity ratio of 0.45.

A number of large investors have recently modified their holdings of PCRX. Louisiana State Employees Retirement System increased its position in shares of Pacira BioSciences by 0.9% during the fourth quarter. Louisiana State Employees Retirement System now owns 21,600 shares of the company’s stock worth $1,300,000 after acquiring an additional 200 shares in the last quarter. Next Capital Management LLC bought a new stake in shares of Pacira BioSciences during the fourth quarter worth $211,000. Exchange Traded Concepts LLC increased its position in shares of Pacira BioSciences by 1.8% during the fourth quarter. Exchange Traded Concepts LLC now owns 9,684 shares of the company’s stock worth $583,000 after acquiring an additional 174 shares in the last quarter. Stonnington Group LLC increased its position in shares of Pacira BioSciences by 1,386.6% during the fourth quarter. Stonnington Group LLC now owns 318,829 shares of the company’s stock worth $19,783,000 after acquiring an additional 297,382 shares in the last quarter. Finally, Gradient Investments LLC increased its position in shares of Pacira BioSciences by 68.0% during the fourth quarter. Gradient Investments LLC now owns 140,173 shares of the company’s stock worth $8,434,000 after acquiring an additional 56,725 shares in the last quarter.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Further Reading: Reverse Stock Split

Earnings History and Estimates for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.